<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03189056</url>
  </required_header>
  <id_info>
    <org_study_id>Chagas_urology</org_study_id>
    <nct_id>NCT03189056</nct_id>
  </id_info>
  <brief_title>Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation</brief_title>
  <official_title>Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Recherche pour le Developpement</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Recherche pour le Developpement</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chagas disease is one of the most neglected vector-borne infectious disease worldwide. The
      first decades following the discovery of the pathology drove an international research
      enthusiasm, mainly concentrated on understanding the typical cardiac and digestive forms.
      Recently, research have been focused on vector control, which has been a huge success, at the
      price of neglecting the patients who already presented fixed and severe organic lesions due
      the chronic phase of the illness.

      This study focus on a rarely studied aspect of this pathology: the involvement of the lower
      urinary tract and it's symptomatology in adults suffering from Chagas chronic disease.

      Various studies have assessed the involvement of the lower urinary tract in chronic Chagas
      disease, the vast majority of them being on the animal model or very ancient human studies
      mainly on cadaveric specimen, the first of them being the primary description of Koeberle in
      1963.

      Human symptomatology deriving from bladder, ureteral and urethral chronic chagasic lesions
      are yet widely unknown, and only a few Brazilian and Mexican studies have intended to
      describe the clinical and urodynamic presentation of these patients.

      The aim of this study is to assess the prevalence of urinary disorders in chronic chagasic
      patients and to describe their symptoms, through a complete clinical, ultrasonographic and
      urodynamic description.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiologic observationnal transversal study

      Cohort of patients between 18 and 50 years of age, presenting a chronic form of Chagas'
      disease (cardiopathy, mega-colon or mega-esofagus), and presenting non of the exclusion
      criteria.

      Recruitment via the existing patients list of positive Chagas serology of:

        -  the SELADIS center (Instituto de Servicios de Laboratorio de Diagnostico e Investigacion
           en Salud UMSA -UNIVERSIDAD MAYOR DE SAN ANDRES-)

        -  Private surrounding hospitals, Hospital de Clinicas and Centro de Seguro Social
           Universitario de La Paz (UMSA)

        -  Laboratorio de Inmunodiagnostico Instituto Boliviano de Biologia de la Altura -IBBA-Dr
           Lourdes Echalar.

      Informed consent signed.

      1 to 3 consultations on a period of one to 2 weeks no follow-up (transversal study)

      Invasive descriptive explorations (blood sample and urodynamic study, imposing the assent of
      the Comité Nacional de Bioética).

      Main objective : Describe the prevalence of the lower urinary tract dysfunction in patients
      suffering from a chronic form of Chagas' disease. The main criteria evaluated is the sum of
      two symptom questionnaires IPSS and ICIQ (spanish official validated translation), focusing
      on urinary incontinence, voiding dysfunction and quality of life.

      Secondary objectives :

      All the included patients will be proposed an initial consult :

        -  Anonymization of all the observation/results

        -  Past history (pathology, actual treatment,…), search of the exclusion criteria, Chagas'
           disease symptomatology and treatment, urological symptomatology.

        -  Validated questionnaires to evaluate urological symptoms, urinary incontinence, voiding
           dysfunction or acute urinary dysfunction, bladder hyperactivity, sexuality and
           fertility.

        -  Clinical examination

        -  Micturition calendar /48hours.

        -  Uroflowmetry, followed by ultrasonography for post-void residual and upper-urinary tract
           dilatation.

        -  Blood sample to evaluate renal function (plasmatic creatinina for CDK EPI formula). This
           blood sample can also be used to confirm the positive Chagas' serology if no serology is
           available (indirect immunofluorescence and ELISA).

      Te participants presenting a symptomatic lower urinary tract dysfunction on the previous
      exams will be proposed a complete urodynamic exploration (cystomanometry, urethral profile,
      pression/flow study during mycturition).

      Sterility of urine assessed before exam. Tecnical material imported from Spain, Albyn medical
      Smardyn and consummables. Electronic curves obtained from Phoenix software (Albyn).

      Objective inclusion of 200 participants during 5 months, between June and October 2017, in
      the SELADIS Institute in La Paz, Bolivia. Director of study Dr Simone Frédérique Brenière
      (french), Bolivian Director of Institute Dra Susana Revollo.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 14, 2017</start_date>
  <completion_date type="Actual">October 20, 2017</completion_date>
  <primary_completion_date type="Actual">October 20, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic patients</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>ICIQ SF&gt;0 IPSS&gt;7 or past acute urinary retention IIEF5&lt;11</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Megabladder</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>Bladder capacity &gt;600cc and &lt;4 daily micturition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mega ureter</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>Ultrasonographic dilatation of renal pelvis&gt;20mm or of ureter &gt;7mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperactive bladder</measure>
    <time_frame>micturition calendar over 2 days (transversal study, the participant will not be followed)</time_frame>
    <description>&gt;8 daily micturition + urgency on dairy subsection detrusor hyperactivity on cystomanometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detrusor underactivity</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>Qmax&lt;15 mL/s and post void residual&gt;150cc per-micturition pressure &lt;40 cm H2O</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal insufficiency</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>CDK EPI&lt;60 mL/mn</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary recurrent infections</measure>
    <time_frame>reported infections duing the last 5 years (transversal study, the participant will not be followed)</time_frame>
    <description>past history &gt; 3 pyélonephritis or &gt;5 cystitis/year in the past 5 years, if associated with dilatated ureter/renal pelvis or significant post void residual</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary sphincter insufficiency</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>P max&lt;30 cm H20 and stress urinary incontinence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erectile dysfunction in males</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>IIEF5 &lt;16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypofertility</measure>
    <time_frame>at consultation : 1 day (transversal study, the participant will not be followed)</time_frame>
    <description>oral assess by difficulty to obtain pregnancy &gt;1 year</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">152</enrollment>
  <condition>Chagas' Disease (Chronic) With Other Organ Involvement</condition>
  <arm_group>
    <arm_group_label>Single cohort</arm_group_label>
    <description>single cohort for transversal study patients presenting chronic chagas disease for all patients : clinical examination/questionnaires/ quality of life/ blood sample for renal function (creatinina) and Chagas serology control if needed/ uroflowmetry/ ultrasonography
If symptomatic patient at first exploration : urodynamic exploration is proposed (cystomanometry, urethral profile, pressure/flow study). No electromyograma. No video urodynamic procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Chagas serology</intervention_name>
    <description>IFI + ELISA method if no biological confirmation of chagas disease is in our possession</description>
    <arm_group_label>Single cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Creatinina</intervention_name>
    <description>Plasmatic single mesure after consultation 1, to evaluate renal function</description>
    <arm_group_label>Single cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urodynamic exploration</intervention_name>
    <description>With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled</description>
    <arm_group_label>Single cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients presenting a chronic form of chagas disease diagnosed by the SELADIS institute
        (serology), by cardiology, gastro-enterology or infectious disease consultation in La Paz
        may be include, after the informed consent have been signed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 50 years of age

          -  Presenting a chronic form of Chagas disease : cardiopathy or enteropathy

          -  Previously treated or not treated

          -  Signed informed consent

        Exclusion Criteria:

          -  Diabetes

          -  Neurologic pathology

          -  Past history of extensive pelvic surgery

          -  Vaginal prolaps &gt; grade 3 of Baden &amp; Walker (female)

          -  Past history of vertebral fracture &gt; L2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elsa BEY, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRD</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SELADIS Institute, Universidad Mayor de San Andrès</name>
      <address>
        <city>La Paz</city>
        <country>Bolivia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bolivia</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/B978-0-12-385863-4.00009-5</url>
    <description>Jelicks, Linda A., et Herbert B. Tanowitz. &quot; Advances in Imaging of Animal Models of Chagas Disease &quot;. Advances in Parasitology 75 (2011): 193‑208. doi:10.1016/B978-0-12-385863-4.00009-5.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2701742/</url>
    <description>Ny, Lars et al. &quot; A Magnetic Resonance Imaging Study of Intestinal Dilation in Trypanosoma Cruzi-Infected Mice Deficient in Nitric Oxide Synthase &quot;. The American Jour</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S0195561609000965</url>
    <description>Barr et al. &quot; Canine Chagas' Disease (American Trypanosomiasis) in North America &quot;. Veterinary Clinics of North America: Small Animal Practice, Small Animal Parasites: Biology and Control, 39, nᵒ 6 (novembre 2009): 1055‑64. doi:10.1016/j.cvsm.2009.06</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1016/j.ijcard.2011.07.060</url>
    <description>Ardito et al. &quot; Chronic Renal Impairment in Patients with Chagas Cardiomyopathy with Chronic Systolic Heart Failure: Prevalence and Prognostic Significance &quot;. Inte</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/14084752</url>
    <description>Koeberle, F. &quot; ENTEROMEGALY AND CARDIOMEGALY IN CHAGAS DISEASE &quot;. Gut 4 (décembre 1963): 399‑405.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/9030871</url>
    <description>Mirkin et al. &quot; Experimental Chagas' Disease: Electrophysiology and Cell Composition of the Neuromyopathic Inflammatory Lesions in Mice Infected with a Myotropic and a Pantropic Strain of</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/12937767</url>
    <description>Cabrine-Santos et al. &quot; Genitourinary Changes in Hamsters Infected and Reinfected with Trypanosoma Cruzi &quot;. Memórias Do Insti</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/10513065</url>
    <description>Scremin, L. H., C. E. Corbett, M. D. Laurenti, E. V. Nunes, J. J. Gama-Rodrigues, et M. Okumura. &quot; Megabladder in Experimental Chagas Disease: Pathological Features of the Bladder Wall &quot;. Revista Do Hospital Das Clínicas 54, nᵒ 2 (avril 1999): 43‑46.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/15745502</url>
    <description>Suaid et al. &quot; Modulation of Urethral Alpha-Sympathetic by Parasympathetic before and Following Bethanechol Chloride Injection &quot;. International Braz J Urol: Official J</description>
  </link>
  <link>
    <url>http://doi.wiley.com/10.1002/ana.410180609</url>
    <description>Said, G�rard, Mireille Joskowicz, Amilton Antunes Barreira, et Harvey Eisen. &quot; Neuropathy Associated with Experimental Chagas' Disease &quot;. Annals of Neurology 18, nᵒ 6 (décembre 1985): 676‑83. doi:10.1002/ana.410180609.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/2851967</url>
    <description>DeFaria, C. R., J. M. De Rezende, et A. Rassi. &quot; [Peripheral denervation in the various clinical forms of Chagas' disease] &quot;. Arquivos De Neuro-Psiquiatria 46, nᵒ 3 (septembre 1988): 225‑37.</description>
  </link>
  <link>
    <url>http://www.sciencedirect.com/science/article/pii/S1383576998805205</url>
    <description>Scremin et al. &quot; T.cruzi induces megabladder in experimental chagas disease &quot;. Parasitology International 47, Supplement 1 (août 1998): 200. doi:10.1016/S1383-5769(98)80520-5.</description>
  </link>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/1590593</url>
    <description>Carraro, A. A., R. A. Lopes, R. D. Ribeiro, et T. L. Lamano Carvalho. &quot; The Male Reproductive Organs in the Chronic Phase of Experimental Chagas' Disease &quot;. Angewandte Parasitologie 33, nᵒ 1 (février 1992): 3‑9.</description>
  </link>
  <link>
    <url>http://dx.doi.org/10.1097/01.ju.0000154170.87947.b8</url>
    <description>Boczko et al. &quot; Trypanosoma Cruzi Infection Induced Changes in the Innervation, Structure and Function of the Murine Bladder &quot;. The Journal of Urology 173, n</description>
  </link>
  <link>
    <url>http://www.scielo.br/scielo.php?script=sci_abstract&amp;pid=S0102-86502001000500003&amp;lng=en&amp;nrm=iso&amp;tlng=pt</url>
    <description>Rocha, J. N., H. J. Suaid, A. C. P. Martins, A. J. Cologna, S. Tucci Jr., et M. A. Gonçalves. &quot; URODYNAMIC ASSESSEMENT IN PATIENTS WITH CHAGAS DISEASE &quot;. Acta Cirurgica Brasileira 16 (2001): 7‑8. doi:10.1590/S0102-86502001000500003.</description>
  </link>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2017</study_first_posted>
  <last_update_submitted>March 26, 2018</last_update_submitted>
  <last_update_submitted_qc>March 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institut de Recherche pour le Developpement</investigator_affiliation>
    <investigator_full_name>Elsa BEY</investigator_full_name>
    <investigator_title>Resident in urological surgery</investigator_title>
  </responsible_party>
  <keyword>chronic Chagas disease</keyword>
  <keyword>bladder</keyword>
  <keyword>lower urinary tract</keyword>
  <keyword>urodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chagas Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

